{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:19:43Z","timestamp":1788369583137,"version":"build-2803163510"},"reference-count":34,"publisher":"American Chemical Society (ACS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,8]],"date-time":"2016-05-08T00:00:00Z","timestamp":1462665600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272200800038C"],"award-info":[{"award-number":["HHSN272200800038C"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We have synthesized and characterized a novel phosphorothioate CpG oligodeoxynucleotide (CpG ODN)-Ficoll conjugated nanoparticulate adjuvant, termed DV230-Ficoll. This adjuvant was constructed from an amine-functionalized-Ficoll, a heterobifunctional linker (succinimidyl-[(N-maleimidopropionamido)-hexaethylene glycol] ester) and the CpG-ODN DV230. Herein, we describe the evaluation of the purity and reactivity of linkers of different lengths for CpG-ODN-Ficoll conjugation, optimization of linker coupling, and conjugation of thiol-functionalized CpG to maleimide-functionalized Ficoll and process scale-up. Physicochemical characterization of independently produced lots of DV230-Ficoll reveal a bioconjugate with a particle size of approximately 50 nm and covalent attachment of more than 100 molecules of CpG per Ficoll. Solutions of purified DV230-Ficoll were stable for at least 12 months at frozen and refrigerated temperatures and stability was further enhanced in lyophilized form. Compared to nonconjugated monomeric DV230, the DV230-Ficoll conjugate demonstrated improved in vitro potency for induction of IFN-\u03b1 from human peripheral blood mononuclear cells and induced higher titer neutralizing antibody responses against coadministered anthrax recombinant protective antigen in mice. The processes described here establish a reproducible and robust process for the synthesis of a novel, size-controlled, and stable CpG-ODN nanoparticle adjuvant suitable for manufacture and use in vaccines.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6b00107","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T19:20:49Z","timestamp":1460575249000},"page":"1293-1304","source":"Crossref","is-referenced-by-count":10,"title":["Optimization, Production, and Characterization of\na CpG-Oligonucleotide-Ficoll Conjugate Nanoparticle Adjuvant for Enhanced\nImmunogenicity of Anthrax Protective Antigen"],"prefix":"10.1021","volume":"27","author":[{"given":"Bob","family":"Milley","sequence":"first","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwan","family":"Kiwan","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Ott","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Calacsan","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kachura","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Kanzler","sequence":"additional","affiliation":[{"name":"MedImmune LLC , One MedImmune Way , , ,","place":["Gaithersburg, Maryland, United States, 20878"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Coffman","sequence":"additional","affiliation":[{"name":"Dynavax Technologies Corporation , 2929 Seventh Street, Suite 100 , , ,","place":["Berkeley, California, United States, 94710"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2016,4,13]]},"reference":[{"key":"2026090213092688800_cit1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/ni1112","article-title":"Toll-like\nreceptor control of the adaptive immune responses","volume":"5","author":"Iwasaki","year":"2004","journal-title":"Nat. Immunol."},{"key":"2026090213092688800_cit2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrc2541","article-title":"Toll-like receptors and cancer","volume":"9","author":"Rakoff-Nahoum","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"2026090213092688800_cit3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"2026090213092688800_cit4","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1016\/j.vaccine.2010.08.002","article-title":"TLR-based immune\nadjuvants","volume":"29","author":"Steinhagen","year":"2011","journal-title":"Vaccine"},{"key":"2026090213092688800_cit5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/erv.10.174","article-title":"CpG DNA\nas a vaccine adjuvant","volume":"10","author":"Bode","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"2026090213092688800_cit6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1586\/14760584.6.5.747","article-title":"Immunostimulatory\nDNA as a vaccine adjuvant","volume":"6","author":"Higgins","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"2026090213092688800_cit7","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development\nof TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J. Clin.\nInvest."},{"key":"2026090213092688800_cit8","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1016\/j.vaccine.2007.01.111","article-title":"Vaccine\nadjuvants revisited","volume":"25","author":"Aguilar","year":"2007","journal-title":"Vaccine"},{"key":"2026090213092688800_cit9","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1016\/j.vaccine.2012.02.001","article-title":"Demonstration of\nsafety and enhanced seroprotection\nagainst hepatitis B with investigational HBsAg-1018 ISS vaccine compared\nto a licensed hepatitis B vaccine","volume":"30","author":"Sablan","year":"2012","journal-title":"Vaccine"},{"key":"2026090213092688800_cit10","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity\nand safety of an investigational hepatitis B vaccine with a toll-like\nreceptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed\nhepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"2026090213092688800_cit11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1208\/s12248-012-9418-6","article-title":"Biodegradable particles\nas vaccine\ndelivery systems: size matters","volume":"15","author":"Joshi","year":"2013","journal-title":"AAPS J."},{"key":"2026090213092688800_cit12","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.1016\/j.vaccine.2014.06.065","article-title":"Clinical evaluation\nof CpG oligonucleotides as adjuvants\nfor vaccines targeting infectious diseases and cancer","volume":"32","author":"Scheiermann","year":"2014","journal-title":"Vaccine"},{"key":"2026090213092688800_cit13","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.4049\/jimmunol.181.5.2990","article-title":"Targeting\nCpG oligonucleotides to the lymph node by nanoparticles\nelicits efficient antitumoral immunity","volume":"181","author":"Bourquin","year":"2008","journal-title":"J. Immunol."},{"key":"2026090213092688800_cit14","doi-asserted-by":"publisher","first-page":"6836","DOI":"10.1182\/blood-2011-07-367615","article-title":"Targeted\ndelivery of TLR ligands to human and mouse dendritic cells strongly\nenhances adjuvanticity","volume":"118","author":"Tacken","year":"2011","journal-title":"Blood"},{"key":"2026090213092688800_cit15","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4049\/jimmunol.1501903","article-title":"A CpG-Ficoll\nNanoparticle Adjuvant for Anthrax\nProtective Antigen Enhances Immunogenicity and Provides Single-Immunization\nProtection against Inhaled Anthrax in Monkeys","volume":"196","author":"Kachura","year":"2016","journal-title":"J. Immunol."},{"key":"2026090213092688800_cit16","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1021\/nn305466z","article-title":"pH-Responsive nanoparticle\nvaccines for dual-delivery of antigens and immunostimulatory oligonucleotides","volume":"7","author":"Wilson","year":"2013","journal-title":"ACS Nano"},{"key":"2026090213092688800_cit17","doi-asserted-by":"publisher","first-page":"19902","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle\nconjugation of CpG enhances adjuvancy for cellular immunity and memory\nrecall at low dose","volume":"110","author":"de Titta","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.\nS. A."},{"key":"2026090213092688800_cit18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jconrel.2013.08.021","article-title":"Multifunctional\nnanoparticles co-delivering Trp2 peptide and CpG\nadjuvant induce potent cytotoxic T-lymphocyte response against melanoma\nand its lung metastasis","volume":"172","author":"Xu","year":"2013","journal-title":"J. Controlled Release"},{"key":"2026090213092688800_cit19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.intimp.2007.04.002","article-title":"Effects\nof intravenous and subcutaneous\nadministration on the pharmacokinetics, biodistribution, cellular\nuptake and immunostimulatory activity of CpG ODN encapsulated in liposomal\nnanoparticles","volume":"7","author":"Wilson","year":"2007","journal-title":"Int. Immunopharmacol."},{"key":"2026090213092688800_cit20","doi-asserted-by":"publisher","first-page":"e94596","DOI":"10.1371\/journal.pone.0094596","article-title":"Combination of liposomal\nCpG oligodeoxynucleotide 2006 and miltefosine induces strong cell-mediated\nimmunity during experimental visceral leishmaniasis","volume":"9","author":"Shivahare","year":"2014","journal-title":"PLoS One"},{"key":"2026090213092688800_cit21","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1093\/nar\/gkg700","article-title":"Novel chimeric immunomodulatory\ncompounds containing short CpG oligodeoxyribonucleotides have differential\nactivities in human cells","volume":"31","author":"Marshall","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"2026090213092688800_cit22","doi-asserted-by":"publisher","first-page":"F1209","DOI":"10.1152\/ajprenal.00097.2007","article-title":"Ficoll is\nnot a rigid sphere","volume":"293","author":"Fissell","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"2026090213092688800_cit23","doi-asserted-by":"crossref","first-page":"704","DOI":"10.4049\/jimmunol.114.2_Part_1.704","article-title":"Thymus-independent\nantigens: the preparation of covalent, hapten-ficoll conjugates","volume":"114","author":"Inman","year":"1975","journal-title":"J. Immunol."},{"key":"2026090213092688800_cit24","first-page":"125","article-title":"Human immune responses in vivo to protein (KLH) and\npolysaccharide (DNP-Ficoll) neoantigens: normal subjects compared\nwith bone marrow transplant patients on cyclosporine","volume":"64","author":"Amlot","year":"1986","journal-title":"Clin. Exp. Immunol."},{"key":"2026090213092688800_cit25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/BF01739010","article-title":"Phase I\/II vaccination\nstudy of recombinant peptide F46 corresponding to the HIV-1 transmembrane\nprotein coupled with 2.4 dinitrophenyl (DNP) Ficoll","volume":"22","author":"Schwander","year":"1994","journal-title":"Infection"},{"key":"2026090213092688800_cit26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/smll.200901158","article-title":"Effect of surface properties on nanoparticle-cell interactions","volume":"6","author":"Verma","year":"2010","journal-title":"Small"},{"key":"2026090213092688800_cit27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics\nand molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"2026090213092688800_cit28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target\ndistinct dendritic cell populations\naccording to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"2026090213092688800_cit29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jim.2007.04.003","article-title":"Formulation\nof vaccines containing CpG oligonucleotides and alum","volume":"323","author":"Aebig","year":"2007","journal-title":"J. Immunol. Methods"},{"key":"2026090213092688800_cit30","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1128\/IAI.73.2.828-833.2005","article-title":"CpG oligodeoxynucleotides adsorbed\nonto polylactide-co-glycolide microparticles improve the immunogenicity\nand protective activity of the licensed anthrax vaccine","volume":"73","author":"Xie","year":"2005","journal-title":"Infect. Immun."},{"key":"2026090213092688800_cit31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1471-2172-4-8","article-title":"Interferon-alpha\/beta\nreceptor-mediated selective induction of a gene cluster by CpG oligodeoxynucleotide\n2006","volume":"4","author":"Kato","year":"2003","journal-title":"BMC Immunol."},{"key":"2026090213092688800_cit32","doi-asserted-by":"publisher","first-page":"151ra126","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced\nantibodies provide cross-species prediction of survival to aerosol\nchallenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2026090213092688800_cit33","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates\nof protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin.\nVaccine Immunol."},{"key":"2026090213092688800_cit34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization\nassay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6b00107","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/27\/5\/1293\/66938042\/acs.bioconjchem.6b00107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/27\/5\/1293\/66938042\/acs.bioconjchem.6b00107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:09:33Z","timestamp":1788368973000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/27\/5\/1293\/772021\/Optimization-Production-and-Characterization-of-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,13]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,4,13]]},"published-print":{"date-parts":[[2016,5,18]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6b00107","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,13]]}}}